Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Non-Current Deffered Revenue: 2017-2025

Historic Non-Current Deffered Revenue for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $53.0 million.

  • Arcus Biosciences' Non-Current Deffered Revenue fell 81.66% to $53.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.0 million, marking a year-over-year decrease of 81.66%. This contributed to the annual value of $234.0 million for FY2024, which is 23.78% down from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Non-Current Deffered Revenue is $53.0 million, which was down 11.67% from $60.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year Non-Current Deffered Revenue high stood at $462.0 million for Q4 2021, and its period low was $53.0 million during Q3 2025.
  • In the last 3 years, Arcus Biosciences' Non-Current Deffered Revenue had a median value of $242.0 million in 2024 and averaged $236.7 million.
  • Per our database at Business Quant, Arcus Biosciences' Non-Current Deffered Revenue spiked by 1,119.29% in 2021 and then slumped by 81.66% in 2025.
  • Over the past 5 years, Arcus Biosciences' Non-Current Deffered Revenue (Quarterly) stood at $462.0 million in 2021, then fell by 23.16% to $355.0 million in 2022, then decreased by 13.52% to $307.0 million in 2023, then dropped by 23.78% to $234.0 million in 2024, then crashed by 81.66% to $53.0 million in 2025.
  • Its Non-Current Deffered Revenue was $53.0 million in Q3 2025, compared to $60.0 million in Q2 2025 and $219.0 million in Q1 2025.